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ABSTRACT
CD20 is a non-glycosylated transmembrane protein expressed on normal B cells,
malignant B cells, and plasma cells, but not their stem cell precursors. It is an ideal target
for antibody therapy because it is not significantly shed or internalized, and CD20
expression is generally not lost after antibody binding. Depleted B cells can also be
regenerated after antibody therapy. Rituximab, a chimeric monoclonal antibody against
CD20, was the first monoclonal antibody to be approved by the FDA for lymphoma.
Results from clinical trials have shown that anti-CD20 monoclonal antibodies, which can
be used unchanged or as carriers for radionuclides or toxins, have significant therapeutic
effects and can be administered with minimal side effects. Several studies have also
shown anti-CD20 monoclonal antibodies to be useful against autoimmune diseases such
as rheumatoid arthritis.
Phage display is an effective tool in genomics and drug development. The ability
to obtain high affinity binders for any antigen with decreased cost and time expenditure
has been useful in the development of therapeutics. Single chain variable fragments
(scfvs) are the smallest antibody fragments which maintain the specificity and the affinity
of the parent antibody. ScFvs can be conjugated to radioisotopes, toxins, drugs, highly
effective Fc region isotypes, and gene delivery vectors, which can be employed in
diagnosis and therapy.
Studies have shown that chimeric and humanized forms of anti-CD20
demonstrate improved clinical efficacy, as compared with murine anti-CD20 monoclonal
antibody, as well as a decrease in HAMA (human anti-mouse antibody) response, which
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is frequently observed with murine antibodies. Although chimerization of murine
antibodies through protein engineering can retain the affinity and specificity of the
parental molecule, this strategy is time-consuming and does not yield the benefit of fully
human antibodies.
To further improve the efficacy of anti-CD20 antibodies, a naïve human scFv
phage library (Tomlinson I+J) was used in the present study to screen for human
antibodies against CD20. A cell based screening strategy was employed in this study by
establishing a tetracycline inducible CD20 CHO cell line, to better mimic the
microenvironment where CD20 and anti-CD20 antibody interaction would occur.
Panning of the phage library against the CD20 transfected cell lines yielded clones with
affinity for CD20 antigen. PCR analysis showed the expected 935bp scFv band, and
monoclonal ELISA showed an affinity for CD20 antigen. Periplasmic protein was
extracted from the clone and subjected to dot blot analysis, showing that in its native
form, Clone 3 had an affinity for CD20. A fusion gene with the CD20 extracellular
domain and an in vivo biotinylation domain was constructed for the isolation and
characterization of antibody fragments. A functional biotinylated CD20 fusion protein
was obtained from bacterial production and western blot analysis under denaturing
conditions yielded a 20kDa band as expected.
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CHAPTER 1
OBJECTIVES
The objective of this project was to isolate and characterize anti-CD20 antibody
fragments by screening a naïve human scFv phage library against cell lines transfected
with the target antigen CD20. A biotinylated CD20 fusion protein expressed in E. coli
was constructed to provide large quantities of fusion protein for the identification and
characterization of the selected antibody fragments.
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CHAPTER 2
REVIEW OF LITERATURE
2.1 Lymphoma and Autoimmune Diseases
Lymphomas are cancers that start in lymphoid tissue. They are classified as
Hodgkin’s Lymphoma or non-Hodgkin’s Lymphoma (NHL) based on their cellular
morphology (American Cancer Society (ACS), 2006). Hodgkin’s Lymphoma is
characterized by Reed-Sternberg cells. Reed Sternberg cells are multinucleate cells
mostly derived from germinal or post-germinal center B cells (Diehl et al., 2003). All
other lymphomas are classified under the NHL category. Non-Hodgkin’s Lymphomas
can be further classified as B-cell NHL, T-cell NHL and natural killer (NK) cell NHL. Bcell NHLs include diffuse large B-cell, follicular lymphomas, marginal zone of mucosaassociated lymphoid tissue (MALT), chronic lymphocytic leukemia (B-CLL), and mantle
cell lymphoma. The two most common types of B-cell NHL: diffuse large B-cell
lymphoma and follicular lymphoma account for about 33% and 14% of NHL cases
respectively. T-cell lymphoma subtypes include lymphoblastic, anaplastic and cutaneous
lymphomas (ACS, 2006). B-cell lymphoma accounts for 85% of all non-Hodgkins
lymphoma cases (Harris et al., 1995 as cited in Multani et al., 2001). The American
Cancer Society estimated 58,870 NHL cases in the United States in 2006 and 18,840
deaths from it (ACS, 2006). B cells are also implicated in the pathogenesis of
autoimmune diseases like lupus and rheumatoid arthritis. Systemic Lupus Erythematosus
(SLE) is an autoimmune disease distinguished by autoreactive T cells, and plasma cells
which produce autoantibodies (Tokunaga et al., 2005). In addition to being precursors to
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autoantibody-secreting plasma cells, B cells play a role in the development of lymphoid
tissue and secrete cytokines, chemokines and growth factors (Sabahi & Anolik, 2006).
Autoantibodies, secreted by plasma cells are also implicated in rheumatoid arthritis, an
autoimmune disease typified by inflammation of the synovium (Edwards & Cambridge,
2001).

2.2 Conventional Therapies
Prior to the FDA approval of monoclonal antibodies, therapy for non-Hodgkin’s
lymphoma consisted of radiation therapy, chemotherapy and bone marrow transplantation.
Radiation therapy is the first line of treatment for patients with stage I and indolent
disease, and is used in combination with chemotherapy for later stage or more aggressive
cancers (NCI, 2007). The head, neck and under the arms, known as the mantle field, are
usually irradiated in NHL. A serious side effect associated with radiation therapy is the
potential for new cancers to arise in the radiation field. The CHOP regimen—
cyclophosphamide, doxorubicin, vincristine and prednisone, is the most common
chemotherapy regimen administered to intermediate grade NHL patients. This regimen
targets rapidly dividing cells, both normal and malignant, leading to a large number of
side effects including a decrease in white blood cell counts, peripheral neuropathy, and
infertility in women (ACS, 2006, Franchi-Rezgui et al., 2003). Peripheral blood stem cell
transplantation (SCT) is used mostly in patients with relapsed intermediate to high grade
lymphomas, or patients who are refractory to conventional therapy (Multani et al., 2001).
In SCT, stem cells are collected from the blood of the patient (autologous) or from a
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matched donor (allogeneic). The patient is subjected to high doses of chemotherapy or
radiation therapy to kill all cancer cells, depleting normal blood and bone marrow cells in
the process. The stem cells are then infused back into the patient to replenish depleted
cells. SCT may lead to the development of leukemia, graft-versus-host disease, and to
death in some patients (ACS 2006, Multani et al., 2001). Most side effects associated
with conventional therapies are due to the non-specific nature of the treatment. Thus
targeted therapy offers ways to improve clinical response while decreasing toxicity.

2.3 Targeted Therapy
Targeted therapy in cancer involves the administration of a substance which
specifically interacts with a molecule which may be directly or indirectly involved in
oncogenesis (Sledge, 2005). These include tumor-associated antigens expressed on the
cell surface, soluble factors, extracellular matrix proteins and proteins associated with
vascularization of tumors. Carter et al., (2004) outline four steps in the identification of
tumor-associated cell surface antigens, and the properties an ideal target should possess.
The first is the procurement of tumor tissue and similar non-tumor cells. Differences
between the tumor and non-tumor tissue are observed on a DNA, mRNA, protein, or
antibody reactivity level to identify the potential target. Antibodies are generated in the
next step to characterize the expression of the target in both tumor and non-tumor tissue.
It is important to validate that the antigen is established on the plasma membrane and its
extracellular components can bind antibody. The last step is in vitro and in vivo screening
of generated antibodies to select clones with desired anti-tumor properties (Carter et al.,

4
.

2004). There are several characteristics an antigen should possess before it can be
deemed an appropriate target for therapy. The expression of the antigen should ideally be
limited to only cancerous cells to decrease any side effects which may result from
targeting of normal cells. This ideal is hardly ever met, thus markers expressed on
nonvital normal cells, or cells which have a means of being replenished are employed.
Presence of the antigen during all stages of cancer broadens the spectrum of cancer
patients treatable with its target substance. Antigens involved in pathogenesis are most
preferred because they are least likely to be down-regulated by the tumor, thus providing
a stable antigen for targeting. Antigens which are not shed are desirable targets for
therapy. Shed antigens may cause antibody clearance before any positive effect is
achieved, and the antibody complexes formed may cause harmful side effects (Carter et
al., 2004). Different types of targeted therapies involve epidermal growth factor receptor
inhibitors, enzyme inhibitors, proteasome inhibitors, angiogenesis inhibitors and
monoclonal antibodies (ASCO, 2006).

2.4 Antibodies
Antibodies are soluble glycoproteins which are secreted by B lymphocytes
(plasma cells) in response to encountered antigen. Antibodies have a molecular mass of
approximately 150kDa and consist of two pairs of light chains (25kDa each) and 2 pairs
of heavy chains (50Kda each). Light chains, which may be kappa or lambda isotype,
consist of one variable domain and one constant domain. A single immunoglobulin
contains only one isotype of light chain, even though no functional difference has been
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found between both isotypes. Each heavy chain consists of one variable domain and three
or four constant domains (CH1-4) depending on the isotype. CH2 domains contain an Nlinked glycosylation site. CH2 and CH3 domains have sequences which are involved in
binding to effector cells and fixation of complement (Vaughan et al., 1998). The class or
overall isotype of an antibody, as well as its effector functions depends on its heavy
chains. These effector functions are performed through the carboxy-terminal of the heavy
chain. Heavy chains can be of an M, A, D, G, and E isotype or class (Janeway et al.,
2001). Heavy chain domains are formed by two beta sheets linked by a disulfide bridge
and interstrand loops (Morea et al., 2000).
At the amino terminal of each chain lies a region of about 110 amino acids which
greatly varies in different antibodies. This is the variable domain which functions in
antigen binding. It comprises the framework regions whose sequence and main
conformation are conserved, and the hypervariable regions which bind specific epitopes
of an antigen. The hypervariable regions or complementarity determining regions (CDR)
comprise six loops: three per variable region. Five of the six loops take on a small
number of main chain conformations called canonical structures. These structures are
dependent upon the length of the loops and key residues which determine the
conformation of the loops (Morea et al., 2000). The information acquired from canonical
structures is useful in the manipulation and modification of antibodies.
Antibodies are an attractive mode of therapy because of their ability to bind
specifically and with high affinity to a vast array of antigens, their stability, and the
relative ease with which they can be engineered or manipulated (Kretzschmar & von
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Ruden, 2002). Antigens are substances which elicit an immune response. An epitope or
antigenic determinant is a portion of the antigen which is recognized by a specific
antibody. After the introduction of an antigenic substance into the body, plasma cells
which recognize its epitopes are activated. The resulting group of antibodies is polyclonal
because it recognizes a multitude of epitopes. Isolating a single monoclonal antibody to a
specific epitope from serum proved difficult. The mortality of B lymphocytes reduced
their usefulness as a source of monoclonal antibodies (Janeway et al., 2001). Georges
Kohler and Cesar Milstein (1975) came up with the hybridoma technique of generating
monoclonal antibodies. A hybridoma is a cell resulting from the fusion of a B
lymphocyte and a myeloma cell. B lymphocytes are isolated from the spleen of mice
injected with the antigen of choice. The B lymphocyte thus provides the ability to
synthesize antibodies to the specific antigen, and the myeloma cells provide immortality.
While this hybridoma technique allowed the isolation and use of countless
monoclonal antibodies, their murine origins limited in vivo use. Clinical murine
monoclonal antibodies stimulated a response known as HAMA (Human Anti Mouse
Antibodies). The body recognizes the murine antibodies as foreign and clears them from
the circulation, reducing their efficacy and causing side effects in the patient. Their
murine origins also mean reduced ability to recruit human effector cell functions, and
inferior pharmacokinetics (Link, 2005). However, because the domain structure of
antibodies is conserved across species, protein engineering enables the manipulation of
antibodies to maintain high binding affinity, decrease immunogenicity and improve
effector cell recruitment (Vaughan et al., 1998).
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Chimeric antibodies were generated to decrease human anti-mouse response.
Chimeric antibodies consist of murine variable regions leaving the antigen binding site
intact, and human constant regions. While immunogenicity is decreased in vivo, some
patients produce human anti-chimeric antibodies which invariably decrease the efficiency
of the chimeric antibody (Pavlou & Belsey, 2005). Both immune responses also decrease
the effectiveness of the drug with increasing number of administrations as the body
builds up a defense against it.
Humanized antibodies sought to decrease further the murine percentage of the
therapeutic antibody, restricting murine portions to only the complementarity determining
regions of the antibody. Both humanized and human antibodies show minimal or no
immunogenicity and the latter allow smaller doses and less frequent administration due to
increased serum half-lives (Pavlou & Belsey, 2005). Different manipulations, such as
pepsin and papain digestion, and sequence manipulation, provided several antibody
fragment types including Fab fragments, Fc regions and scFvs, which can be employed in
therapy.

2.5 Single Chain Variable Fragments
Single chain variable fragments (ScFvs) are the smallest antibody fragments
which retain the complete antigen binding site of the parent antibody (Leath et al., 2004).
An ScFv is expressed as one polypeptide chain, encoded by a single gene (Blazek &
Celer, 2003). They are composed of the variable regions from heavy (VH) and light
chains (VL), linked covalently by a flexible peptide which prevents dissociation (Holliger
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& Hudson, 2005). This covalent bond enhances the association of the two domains after
folding. The carboxy terminal of the VH is linked to the amino terminal of the VL,
allowing the same molar concentration of both variable fragments to be expressed.
Various types of linkers have been designed to connect the two domains. Some were
designed to have minimal interaction with the variable fragment, while another set
consisting of alternating serine and glycine residues were designed to fit into a groove in
the back of the fragment (Bird et al., 1988). ScFvs are usually obtained from
immunoglobulin G and retain not only its specificity, but also the affinity with which it
binds antigen (Holliger & Hudson, 2005). Prior to the use of in vitro display techniques
to isolate antibodies and antibody fragments, mRNA was isolated from a hybridoma,
reverse transcribed and the antibody gene segments amplified via PCR (Blazek & Celer,
2003). The introduction of phage and ribosomal display libraries decreased the time
involved in the generation of highly specific single chain fragments.
Antibodies and their fragments are employed in the identification, isolation, and
characterization of cell surface molecules, from which new targets for treatment can be
identified. In diagnostics, antibodies can be used to determine different cell types present
in serum, and their cell counts (Zola, 2006). ScFvs can also bind and neutralize viruses
and toxins. ScFvs with neutralizing activity against human cytomegalovirus
glycoproteins and HIV-1 Tat antigen have been isolated and characterized (Blazek &
Celer, 2003, Moreau et al., 2003). The quick tumor penetration, rapid clearance from
circulation, and increased tumor-to-blood ratio of antibody fragments makes them great
candidates for the diagnosis and therapy of cancer (Verhaar et al., 1996). Radionuclides
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like Technetium-99 have been coupled to tumor antigen specific scFvs to aid in tumor
imaging and dosimetry (Verhaar et al., 1996, Blazek & Celer, 2003). Antibody fragments
can also be equipped to deliver toxins to cancer cells. The antibody target should
however internalize after binding, and the enzyme fragment of the toxin should be able to
translocate to the cytosol. Toxins usually employed include Pseudomonas exotoxin (PE)
and truncated diphtheria toxin (Kreitman, 2006). Phase I clinical trials with SS1P an antimesothelin-PE-conjugate, in mesothelioma, ovarian cancer, and pancreatic cancer
patients showed improved response (Hassan et al., 2004). ScFvs have been used to
improve specificity and to decrease immunogenicity of gene therapy vectors. An
adenoviral vector including a gene for an anti-erbB2 scFv administered intraperitoneally
to ovarian cancer patients, showed no vector-related toxicity and downgraded 38% of
patients in the study from recurrent to stable disease (Alvarez et al., 2000 as cited in
Leath et al., 2004).

2.6 Phage Display
In vitro display techniques are a cheaper and considerably faster means of
obtaining a vast array of human antibodies and antibody fragments. The most prevalent in
vitro selection technique is phage display. The basic principle in display technology is
the direct link between phenotype and genotype (Holt et al., 2000). The genes encoding
the fusion protein and its display are packaged into the phage particle as a single stranded
DNA molecule, during the assembly of phage particles. This ensures that all phage from
a single bacterial colony are identical (Paschke, 2005).
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The displayed proteins are the result of fusion between a phage capsid protein and
the protein or antibody fragment of choice. Phage libraries contain large numbers of
phage exhibiting different proteins on their surface. Phage display allows the isolation of
high affinity, fully human antibodies in a short time and with high throughput (Vaughan
et al., 1998, Kretzschmar & von Ruden, 2002). The most common phage used in phage
display is the filamentous non-lytic M13, where the antibody fragment is fused to its
minor capsid protein pIII, or major capsid protein pVIII (Kretzschmar & von Ruden,
2002, Paschke, 2005). There are about 2700 molecules of the 5kDa pVIII expressed to
form a cylinder which encases the phage genome. Three to five molecules of pIII, which
has a molecular weight of about 42kDa, are expressed at one end of a phage particle. pIII
consists of three domains: CT at the carboxyl terminal, and N1 and N2 at the amino
terminal. N2 binds to the F pilus to start the infection process, while CT may play a role
in the translocation of DNA (Webster, in Kay et al., 1996, Paschke, 2005).
Phage display systems can be divided into two groups based on the vectors used
to acquire phage. Ff phage (M13, fl and fd) are 98% homologous filamentous phage
which are capable of infecting gram negative bacteria bearing the F conjugative plasmid
(Webster, in Kay et al., 1996, Paschke, 2005). The first group of phage vectors is derived
from the genome of Ff phage, and contains all the genetic information required for
replication and phage particle assembly. The fusion protein can be produced by the
modification of the capsid protein or by inserting a gene cassette which encodes for the
fusion protein. In the latter example, the phage displays both wildtype and fusion coat
proteins. The second group involves the use of phagemids, and generally gives rise to
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phage which express both wildtype and fusion coat proteins (Paschke, 2005). A
phagemid is a plasmid which contains an origin of replication and a packaging signal
from a filamentous phage, as well as an origin of replication and gene expression systems
from a bacterial plasmid. A phagemid is able to maintain itself as a plasmid in bacteria, in
the absence of phage infection. The phage origin of replication is activated when the host
bacteria is infected by helper phage (Webster, in Kay et al., 1996). In this system,
phagemids make the fusion protein. However, all the proteins needed for other functions
including replication and packaging are provided by a helper phage, which co-infects the
same bacterial cell. The helper phage then packages the single stranded phagemid DNA.
However, helper phage is also capable of packaging its own genome, resulting in phage
particles which do not express the fusion protein. Helper phages with defective origins of
replication or defective packaging signals can be employed in order to encourage
packaging of phagemid DNA over helper phage genome (Russel et al., 1996; Vieira &
Messing, 1987, as cited in Paschke, 2005). Ff phage display three to five copies of pIII on
their surface, limiting the amount of fusion protein expressed. It has however been shown
that during phage assembly, wild type pIII is packaged over the fusion product. While
this aids in avoiding the effects of avidity, the diversity of the system is reduced. This can
be overcome by engineering the helper phage to package only the pIII fusion protein.
Another option was to eliminate the infectivity of packaged phage particles which
expressed wildtype pIII by introducing a protease restriction site between the N1 and N2
domains. Thus, only phage particles which express the fusion protein are capable of

12
.

infection (Rondot et al., 2001; Kirsch et al., 2005; Kristensen & Winter, 1998; as cited in
Paschke, 2005).
Phage libraries can be naïve, immune or synthetic. Naïve libraries are generated
from antibodies which have yet to encounter antigen. Immune libraries are specific for a
particular antigen. Naïve libraries are employed in the search for antibodies against any
antigen. They are also a better source of antibodies to cell surface markers compared to
immune libraries. Self reactive antibodies removed by tolerance mechanisms may include
antibodies reactive to cell surface markers, thereby reducing the availability of these
antibodies to immune libraries (Kretzschmar & von Ruden, 2002, Roovers et al., 2001).
Holt et al., (2000) define naïve libraries as natural, synthetic, or targeted. Natural libraries
comprise naturally rearranged genes obtained from human B lymphocytes. Synthetic
libraries involve the in vitro rearrangement of human germline antibody genes by PCR.
Targeted libraries consist of optimized human antibody frameworks, with specific
residues in the antigen binding site diversified (Holt et al., 2000).
Phage libraries should possess certain characteristics which would enable the
selection of useful antibodies. Kretzschmar and von Ruden (2002) describe these
collectively as ‘high quality’ libraries. First, the library should have a large functional
size with great sequence diversity, to enable the selection of antibodies with high affinity.
Naïve libraries are usually 107 to 1010 in size (Holt et al., 2000). The antibody genes need
to be stably expressed in order to retain their characteristics during panning and screening
processes. The design of the library should also allow rapid manipulation of chosen
antibodies (Kretzschmar and von Ruden, 2002).
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2.7 CD20
CD20 is a non-glycosylated transmembrane differentiation antigen that is
expressed on all B cells with the exception of pro-B cells and activated plasma cells. The
CD20 molecule is encoded by a 16kb single copy gene, which comprises eight exons
(Tedder et al., 1989). Due to differences in phosphorylation of serine and threonine
residues, CD20 is expressed in three forms: 33, 35 and 37Kda (Tedder et al., 1988, 1993
as cited in Tedder & Engel, 1994). CD20 is a member of the MS4A (membrane spanning
4 domains, subfamily A) gene family, along with the β chain of the IgE receptor, FcєRI.
FcєRI β and CD20 are similar in structure and the genes for both molecules are found on
chromosome 11q (Cragg et al., 2005). CD20 comprises a long hydrophobic chain which
passes through the cell membrane four times, creating two extracellular fragments. The
larger of these two fragments has an Ala X Pro motif which is important for antibody
binding (Cragg et al., 2005). Both the amino and carboxy terminals of CD20 are in the
cytoplasm (Tedder & Engel, 1994, Tedder et al., 1989). Cross-linking and
immunoprecipitation experiments have shown that CD20 complexes to form homodimers
and homotetramers. CD20 also associates with CD40, MHCII and B-Cell receptor (BCR)
molecules on the cell surface (Tedder & Engel, 1994, Leveille et al., 1999, Petrie &
Deans, 2002, as cited in Cragg et al., 2005).
The structure of CD20, along with its similarities to FcєRI β, suggested that CD20
may form a membrane channel (Cragg et al., 2005). Bubien et al., (1993) showed that
CD20 may play a role in calcium conductance. CD20-negative cell lines which were
transfected with CD20 showed an increase in the basal level of cytosolic calcium. They
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also demonstrated that calcium uptake was higher in CD20 transfectants than equivalent
controls, after the re-introduction of calcium to calcium-depleted cells (Bubien et al.,
1993, Tedder & Engel, 1994). B1, a murine IgG2a anti-CD20 monoclonal antibody,
causes improved progression from cell cycle phase G0 to G1. However, 1F5, a different
anti-CD20 monoclonal antibody of the same isotype, blocked the passage from G1 into S,
G2 and M phase (Golay et al., 1985, Tedder et al., 1986, as cited in Cragg et al., 2005).
Experiments on Daudi cells showed that B1 induced a slow increase in cytoplasmic
calcium upon binding, while 1F5 induced a rapid calcium flux. These results suggest that
the differences in effect on cell cycle progression may be enabled through their effects on
calcium levels (Cragg et al., 2005). CD20 knockout mice had reduced B cell IgM
expression and CD19-induced intracellular calcium responses were reduced. However,
other B cell characteristics and functions were normal. This suggests that CD20 is not
ultimately vital to the survival of B cells. Alternatively, other MS4A genes may
contribute to calcium ion transport, and despite their 73% amino acid homology, mouse
and human CD20 may be regulated differently (Uchida et al., 2004, Cragg et al., 2005).
Though CD20 has no known natural ligand, it is capable of generating transmembrane
signals when bound by a CD20 specific monoclonal antibody (Cragg et al., 2005).
However, the type of response depends on the specific antibody. Cragg and Glennie
(2004a) classified anti-CD20 monoclonal antibodies into 2 groups based on their ability
to eliminate lymphoma xenografts: type I monoclonal antibodies which use complement
and Type II which do not.
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Several sets of experimental data support the idea that complement-dependent
mechanisms are a major factor in the therapeutic effect of type I anti-CD20 monoclonal
antibodies. It has been shown that complement is depleted during treatment with
rituximab, a type I antibody (van der Kolk et al., 2001 as cited in Cragg et al., 2005). The
consumption of complement by cobra venom factor reduced the efficiency of rituximab
and 1F5 in lymphoma xenograft models, but not of B1, a type II monoclonal antibody.
Rituximab and 1F5 were also shown to bind C1q, which initiates the classical
complement pathway, and deposit C3b (Cragg & Glennie, 2004a). Some cells remaining
after anti-CD20 therapy have increased levels of CD59, a molecule which prevents the
formation of the membrane attack complex during the classical complement pathway.
This suggests that these cells have been subject to complement during antibody therapy
(Bannerji et al., 2000, Treon et al., 2001, as cited in Cragg & Glennie, 2004b). While
both antibody types have comparable association rates, the maximum level of Type II
binding, is approximately half the maximum level of Type I monoclonal antibodies
(Chan et al., 2003, Teeling et al., 2004). Other differences between the two groups have
been demonstrated. Type I monoclonal antibodies like 1F5 cause the redistribution of
CD20 into Triton X-100-insoluble lipid rafts. Type II monoclonal antibodies like B1 do
not cause the redistribution of CD20, but are effective at inducing apoptosis and
homotypic adhesion (Chan et al., 2003, Cragg et al., 2005).
Shan et al., (1998) demonstrated that crosslinking of CD20 with murine antiCD20 monoclonal antibodies in the presence of Fc-receptor bearing cells, inhibits B-cell
proliferation, causes fragmentation of nuclear DNA, and leads to apoptosis. Apoptosis
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was however obstructed by the addition of calcium ion chelating agents. This suggested
that the binding of the antibodies may induce signal transduction events which ultimately
lead to apoptosis (Shan et al., 1998). Comprehensive depletion of CD20-positive cells in
B-CLL patients treated with rituximab was shown to correspond to apoptosis, as
evidenced by the blood levels of apoptotic by-products (Byrd et al., 2002, as cited in
Chan et al., 2003). Bannerji et al., (2003) also showed that high levels of complement
dependent cytotoxicity (CDC) and apoptosis regulatory proteins in CLL patients
corresponded with resistance to rituximab treatment. Experiments with Fab fragments
however showed that apoptosis could occur independent of the Fc portion. The levels of
apoptosis observed were comparable to levels obtained with complete antibodies. In
agreement with Shan et al., (1998), crosslinking was required, and was achieved through
the use of bivalent antibody fragments (Shan et al., 1998, Chan et al., 2003, Ghetie et al.,
2001).
Both type I and type II antibodies induce similar antibody dependent cellmediated cytotoxicity (ADCC) (Teeling et al., 2004, Cragg et al., 2005). An IgG4 variant
of rituximab, which is less effective at recruiting effector cells than the IgG1 original,
was unable to deplete B cells (Anderson et al., 1997, as cited in Cragg & Glennie, 2004a).
This was one of the first hints that anti-CD20 antibodies used Fc-dependent mechanisms.
F(ab)2 fragments derived from type I anti-CD20 monoclonal antibodies had no
therapeutic effect in Burkitt’s lymphoma xenograft models, further supporting Fcdependent mechanisms as a factor in anti-CD20 antibody therapy (Cragg & Glennie,
2004b). Non-Hodgkin’s lymphoma patients expressing the 158V allotype of Fc-gamma-
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RIIIa, a higher affinity variant of Fc receptor, showed better response rates to rituximab,
than patients with the low affinity 158F allotype. While this lends more support to the
importance of Fc receptor mediated mechanisms in anti-CD20 therapy in non-Hodgkin’s
lymphoma, Farag et al., (2004) showed that allotype is not an indicator of response in
chronic lymphocytic leukemia (Cartron et al., 2002, Farag et al., 2004 as cited in Cragg &
Glennie, 2004b). Binding of most anti-CD20 monoclonal antibodies leads to increased
CD20 phosphorylation, increased expression of MHCII molecules, the downregulation of
interleukin-10, and the activation of src-kinases, phospholipases, and caspases (Tedder et
al., 1988, Clark et al., 1987, White et al., 1991 as cited in Tedder & Engel, 1994, Johnson
& Glennie, 2003). In summary, in vivo and in vitro evidence point to ADCC, CDC and
apoptosis as the major mechanisms through which anti-CD20 monoclonal antibodies
achieve their therapeutic effect (Cragg et al., 2005).
CD20 is a great target for antibody therapy for a number of reasons. It is
expressed on about 95% of all B cell lymphomas (Davis et al., 1999), and its expression
is limited to cells of B lineage, allowing for increased tumor specificity. Among these
cells, pro-B cells, hematopoietic stem cells and plasma cells do not express CD20. The
first two allow for recovery after treatment, and the last helps maintain immunoglobulin
levels (Cragg et al., 2005). CD20 has a high antigenic density: there are 100,000-400,000
CD20 molecules per lymphoma B cell. This allows for improved targeting, and increased
effector cell response (Cragg et al., 2005, Press et al., 1989). CD20 is not shed after
binding, nor is it internalized, which means improved ADCC and CDC, and also makes
CD20 a good target for radioimmunoconjugates. Targets which are internalized upon

18
.

binding lead to quicker break down and removal of the radioisotope, decreasing the
effectiveness of the conjugate (Glennie & van der Winkel, 2003). The occurrence of
CD20-negative variants after treatment is generally not common, allowing the repeat use
of antibody therapy (Cragg et al., 2005).

2.8 Current Anti-CD20 Monoclonal Antibodies
Rituximab, a type I chimeric monoclonal antibody was the first monoclonal
antibody to be FDA approved for the treatment of cancer. It was approved in 1997 for the
treatment of low-grade B-cell Non-Hodgkin’s Lymphoma (Cartron et al., 2007).
Rituximab is also used in combination with chemotherapy for diffuse large B cell
lymphoma and follicular lymphoma. In a study of elderly diffuse large B-cell lymphoma
patients, the addition of rituximab to CHOP regimen increased the complete response rate
and overall survival of the patients without increased toxicity (Coiffier et al., 2002).
Similar results were observed when rituximab was added to CVP (cyclophosphamide,
vincristine, and prednisone) for follicular lymphoma (Imrie et al., 2005).
Rituximab is a chimeric antibody comprising light and heavy variable chains from
the murine anti-CD20 antibody 2B8, human IgG1 heavy chain, and human kappa light
chain (Reff et al., 1994). Due to its ability to deplete B cells, rituximab has proven useful
in therapy of a number of hematological diseases. Idiopathic thrombocytopenic purpura
(ITP) is an autoimmune disease where platelets are destroyed by being opsonized by
autoantibodies (Cines et al., 2002, as cited in Braendstrup et al., 2005). Braendstrup et al.,
(2005) and others have shown a 50% response rate in ITP patients treated with rituximab.
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In a study, rheumatoid arthritis patients treated with rituximab, cyclophosphamide and
prednisolone, showed improvements which lasted beyond six months (Edwards &
Cambridge 2001). Rituximab has since been FDA-approved in combination with
methotrexate to decrease symptoms in adult rheumatoid arthritis patients who had
insubstantial response to tumor necrosis factor (TNF) antagonists (Biogen Idec &
Genentech, 2007). In a small study with refractory SLE patients, rituximab was shown to
reduce B-cell numbers and improve the condition of patients with SLE-associated
ailments. Patients did not relapse even after B-cell counts returned to normal (Tokunaga
et al., 2005). This could be explained by results obtained by Anolik et al., (2004) where
rituximab was shown to settle deviations in SLE patients exhibiting aberrant B cell
homeostasis.
Despite its successes, a significant group of NHL patients do not respond to
rituximab. This may be due to CD20 being expressed heterogeneously, or the impairment
of ADCC and CDC mechanisms which play a role in the efficacy of rituximab. Even with
responsive patients, there is a chance of relapse (Schaefer-Cutillo et al., 2007). In some
SLE patients, rituximab was shown to cause reactivation of JC virus, a polyoma virus
implicated in progressive multifocal leukoencephalopathy (PML), a viral infection of the
brain (FDA, 2006).
Zevalin, an anti-CD20 immunoconjugate was FDA-approved as part of a regimen
including rituximab for the treatment of relapsed or refractory follicular, low-grade, or Bcell NHL in 2002. It was also approved for treatment of rituximab-refractory follicular
NHL (FDA, 2002). It is a murine IgG1 kappa monoclonal antibody, ibritumomab, linked
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to yttrium-90 for therapy, or indium-111, for imaging and to evaluate the biodistribution
of ibritumomab, via tiuxetan (Spies, 2004). Tiuxetan is a high affinity linker and chelator
for yttrium-90 and indium-111 which is covalently bound to the monoclonal antibody
(Krasner & Joyce, 2001, Wiseman et al., 2002, Biogen Idec, 2006, Witzig, 2001).
Yttrium-90 is a pure beta-emitter with a half-life of 64hrs. The path length for which
greater than 90% of the energy emitted is absorbed is 5.3mm. These characteristics
enable efficient delivery of radiation to cancer cells (Knox et al., 1996, Biogen-Idec,
2006). In a randomized study, 30% of B-cell NHL patients treated with Zevalin and
rituximab had a complete response, as assessed by an independent panel, versus 16% of
patients treated with rituximab alone (Witzig et al., 2002).
Bexxar is an immunoconjugate comprising a murine IgG2a lambda monoclonal
antibody tositumomab, covalently linked to Iodine-121. In 2003, tositumomab and
Bexxar were FDA approved for treatment of CD20 positive follicular NHL, which was
rituximab-refractory or had relapsed after chemotherapy (FDA, 2007). Iodine-131 emits
beta and gamma rays, with a path length of 0.8mm, and a half life of about 8 days. In
addition to antibody mediated destruction of cells, radiation emitted by Iodine-131 kills
tumor cells in contact with the antibody as well as tumor and normal cells nearby via
‘bystander effect’. Bexxar and Zevalin have the best results when used as single agents
for their approved malignancies in comparison to other anti-CD20 antibodies (SchaeferCutillo et al., 2007).
Humax-CD20 (Ofatumumab) is a fully human anti-CD20 IgG1 monoclonal
antibody 2F2, currently in Phase III trials for the treatment of NHL, CLL, and rheumatoid
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arthritis (Genmab, 2007). 2F2 is a type I monoclonal antibody, which is excellent in CDC
and is capable of lysing rituximab-resistant CLL cells. In comparison to rituximab, 2F2
had significantly lower dissociation rates, which could account for its increased CDC
potency, and makes it a good choice for the construction of radioconjugates (Teeling et
al., 2004). A human anti-CD20 monoclonal antibody, engineered to have a faster
dissociation rate than rituximab was still comparatively potent in CDC, suggesting that
CDC potency was not completely dependent on dissociation rate (Teeling et al., 2006).
Clinical studies showed favorable response in NHL patients who were refractory to
rituximab and patients who had previously responded to rituximab treatment. No dose
limiting toxicity was reported for Humax-CD20 during the study. Studies in patients with
CLL and rheumatoid arthritis also showed high response rates (Genmab, 2007). Teeling
et al., (2006) developed a panel of completely human anti-CD20 antibodies which do not
rely on the AxP motif in the CD20 extracellular fragment for binding. A 15 amino acid
segment N-terminal of the AxP motif was shown to be the binding site. These antibodies
did not need high CD20 cell surface density to cause cell lysis in comparison to rituximab
(Teeling et al., 2006).
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CHAPTER 3
MATERIALS AND METHODS
3.1 Cell Lines
A Tetracycline-regulated Expression (T-Rex™) CHO cell line stably expressing
the tetracycline (Tet) repressor and designed for use with the T-REx™ System was
obtained from Invitrogen. 293T/17 and Raji cells were obtained from ATCC (ATCC#
CRL-11268, and CCL-86 respectively). 293T/CD20 cells were a gift from Dr. P. Wang
(University of Southern California). All cells were cultured according to the suppliers’
protocols.

3.2 Construction, Expression, and Refolding of a Biotinylated Fusion Protein
Containing the Extracellular Domain of CD20
RNA was extracted from Raji Cells and reverse transcribed into cDNA. Primers
CD20Foward (5’-TTTGAGAGCAAAATGACAACACCCAGA-3’) and
CD20Reverse (5’-AGAAGAAATCACTTAAGGAGAGCTGTC-3’) were designed to
amplify the 894bp CD20 ORF. The resulting fragment was ligated into PCR 2.1 vector
(Invitrogen). Competent Top 10 E coli cells were transformed with vector which had
CD20 ORF in the correct orientation. The extracellular fragment of CD20 which falls
between nucleotides 418 to 571 in the CD20 ORF was then amplified using primers
CD20-EC Forward (5’- TCGCGAAAATATTAAAAT TTCCCATTTTTTAAAAATG-3’)
and CD20-EC Reverse (5’-TTAGAACAGAGATTGTATGCTGTAACAGTA-3’),
designed to amplify the extracellular fragment, as well as introduce an NruI restriction
site and a TAA stop codon. This cDNA fragment was ligated into the Pinpoint Xa-1
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Vector (Promega, Madison, WI) in frame with the in vivo biotinylation fragment to form
a fusion gene. Rosetta E. coli cells (Novagen) were transformed with the ligation reaction
and cultured on LB plates overnight. A single colony was picked and cultured overnight
in LB medium with biotin and induced with IPTG (100µM) at 37°C for 4hrs. The
cultures were centrifuged and pellets resuspended in PBS. After sonication with a
Branson Sonifier (VWR Scientific), the cells were centrifuged and the supernatant
discarded. The pellet was resuspended in wash solution (0.5% Triton X100, 50mM trisHCL pH8, 100mM NaCl and 0.1% sodium azide) using a homogenizer on ice. The
homogenized sample was centrifuged at high speed for 10min and the supernatant
discarded. This wash was repeated five times. The resulting pellet was resuspended in
30ml buffer (8M Urea, 50mM Tris pH 8, 100mM NaCl, 10mM EDTA, and 10mM DTT)
and placed on a rocker at room temperature overnight. The sample was centrifuged and
the precipitate discarded. The protein was refolded by dialyzing against refolding buffers
(50mM Tris pH 8, 100mM NaCl, 10mM EDTA, and 10mM DTT) with decreasing
concentrations of urea (8M, 6M, 4M, 2M, 1M, 0.5M) at room temperature for 4 hours at
each urea concentration. The sample was finally dialyzed against water at 4°C overnight.
This refolding protocol was adapted from Rudolph and Lilie (1996).

3.3 Construction of a Tetracycline Inducible CD20 Expression Vector
The CD20 cDNA sequence from the UltimateTM ORF plasmid was obtained in the
pENTRTM221 vector (Invitrogen) and then transferred into the pT-Rex-DEST30 vector
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through an LR recombination reaction with the Gateway® LR ClonaseTM Enzyme Mix
(Invitrogen) according to the manufacturer’s instructions.

3.4 Establishing a CHO Cell Line with Tetracycline Inducible CD20 Expression
A T-75 flask of T-REx CHO cells at 60% confluency was trypsinized and
suspended in media. A small volume (1.2ml) was made up to 12 ml with media. Two
milliliters was added to each well of a six well plate, and left to grow overnight at 37°C
in a 5% CO2 incubator. CD20 plasmid DNA (1µg, 2µg) was diluted in Opti-MEM® I
reduced serum media (50µl, Invitrogen). Lipofectamine™ (2.5µl, 5µl, Invitrogen) was
diluted with Opti-MEM® I medium. This was incubated for 5min at room temperature.
The diluted DNA and diluted Lipofectamine™ were mixed and incubated at room
temperature for 20min. The complex formed (100µl) was added to each well. The cells
were incubated overnight at 37°C in a 5% CO2 incubator. The media was replaced the
following day.
Two days following transfection of the T-REx CHO cells, the wells were
incubated with media containing Geneticin (2mg/ml, 4mg/ml, Gibco). The geneticin
resistant cells were transferred to a T-25 flask and cultured in 2mg/ml geneticin. At about
60% confluency, tetracycline hydrochloride (Sigma) was added to each flask to a final
concentration of 1µg/ml to induce CD20 protein expression. Twenty-four hours later, the
cells were harvested and protein was extracted for Western blot analysis.
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3.5 Western Blots
Protein was extracted from T-REx CHO cells, CD20 transfected T-REx CHO
cells, and tetracycline induced CD20 transfected T-REx CHO cells. A western blot was
done under denaturing condition using a 1:250 dilution of mouse anti-CD20 antibody
(Abcam) as the primary antibody, and a 1:2000 dilution of goat anti-mouse HRP
conjugate (Bio-Rad) as the secondary antibody. Complexes were visualized using ECL
Detection reagents (Amersham, Piscataway, NJ).

3.6 Phage Library
Human single fold scFv libraries I + J (Tomlinson I + J) were obtained from MRC
Laboratories (Cambridge, UK). The libraries consist of over 108 different scFv fragments
cloned into an ampicillin-resistant phagemid vector, and transformed into TG1 E coli
cells. KM13, a protease sensitive helper phage to aid in the propagation of phage, and
HB2151, a non-amber suppressor strain of E Coli for the production of soluble antibody
fragments were included (Geneservice, Cambridge, UK).

3.7 Phage Propagation:
KM13 and Libraries I and J were propagated according to manufacturer’s
instructions (Geneservice, Cambridge, UK). A library stock (500µl) aliquot was added to
200ml of 2xTy with 100µg/ml Ampicillin and 1% glucose and incubated with shaking at
37°C until the O.D. 600 was 0.4. 50 ml of this culture was infected with 2 x 1011 KM13
in a 37°C water bath for 30min. After centrifugation at 3,000g for 10min, the pellet was
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resuspended in 100ml 2xTY with 100µg/ml Ampicillin, 50µg/ml Kanamycin, and 0.1%
glucose, and the culture was incubated with shaking at 30°C overnight. The overnight
culture was spun at 3,300g for 30min. A 20 ml solution of 20% Polyethylene glycol 6000
and 2.5M NaCl was mixed with 80ml supernatant and left on ice for 1hr. The mixture
was spun at 3,300g for 30min. The pellet was resuspended in 4ml PBS and spun at
11,600g for 10min. The phage-containing supernatant was recovered and kept at -80OC.
To titer the recovered phages, 1µl of the phage stock was serially diluted into 100µl PBS
six times. Each dilution was mixed with 900µl of TG1 E coli cells cultured until an O.D.
600 of 0.4 and incubated for 30min in a 37°C water bath. 10µl from each dilution was
then spotted onto TYE plates and incubated overnight at 37°C.

3.8 Cell-based Phage Selection Procedure
This protocol was adapted from Heitner et al., (2006). Briefly, 293T/17 cells (1 x
109) were spun down and resuspended in 5ml blocking buffer (2% BSA, 10% FBS in
PBS) and incubated at 4°C with rotation for an hour. The cells were divided into 3 tubes.
1x1010 pfu of phage from the original library (I+J) in blocking buffer were incubated
sequentially with the three tubes of cells for a half hour each time, with rotation. The
screened phages were incubated with a pellet of 293T/CD20 for 2hrs, which had been
previously blocked, for 1hr at 4°C. The cells were washed with blocking buffer 10 times
(1000rpm, 5min). The binding phages were then eluted with 0.5ml 0.1M triethanolamine
and neutralized with 1ml 1M Tris-HCL pH 7.5. Log phase TG1 (OD600 of 0.4) was
infected with 250µl of the eluted phage. The phage was then amplified, and titered.
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This protocol was repeated using eluted phage from the previous step. The resultant
phage was used in the same protocol, with T-REx CHO cells as the depleting cell line,
and CD20 transfected T REx CHO cells which had been induced for 24hrs as the
selective cell line. This was repeated with decreasing incubation time in subsequent
rounds from 2hrs to 1hr and to 30min, while increasing the number of washes from 10 to
15 and to 20.

3.9 Polyclonal Phage ELISA
A 96 well plate was coated overnight at 4°C with 100µl per well of 10µg/ml
recombinant GST tagged CD20 protein (Abnova, Taiwan). The wells were washed and
blocked with blocking buffer (2% non-fat dry milk in PBS) for 2hrs with rotation at room
temperature. Phage from each round (1 x1010) in blocking buffer (100µl) was added to
the wells for 1hr. After washing with 0.1% Tween in PBS, a 1:5000 dilution of HRP
conjugated Anti-M13 antibody (Pharmacia) in blocking buffer was added and incubated
for 1hr. Media (2xTY) and library phage were used as controls.

3.10 Monoclonal Phage ELISA
Colonies were picked from titer plates and grown overnight in 2xTY (100µg/ml
Ampicillin, 1% glucose). An inoculum was transferred to 200µl of media and grown for
2hrs. The culture was infected with 1 x1010 helper phage for 1hr. The resulting pellet was
resuspended in media (2xTY, 100µg/ml Ampicillin, 50µg/ml Kanamycin) and grown at
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30°C overnight. The supernatant after centrifugation was used in ELISA as described
above, using HRP-Anti M13 (Pharmacia) as the secondary antibody.

3.11 PCR Screening:
Colonies were directly screened by PCR to determine the presence of scFv inserts.
The primers LMB3 and pHEN (Geneservice, Cambridge, UK) were used under the
following conditions:
Denaturation: 94°C for 9min
30 cycles of: Denaturation: 94°C for 45sec
Annealing: 55°C for 45sec
Elongation: 72°C for 45sec
Final Elongation: 72°C for 5min.
This was adapted from MRC (Geneservice, Cambridge, UK).
The PCR products were run on a 1% agarose gel.

3.12 Extraction of Periplasmic Protein
Phage was obtained from chosen clones using the phage propagation protocol.
Log phase HB2151 was infected with the phage in a 37°C water bath for 30min. Several
dilutions were plated out. HB2151 clones were then grown overnight and used as an
inoculum for a larger culture (350ml) which was grown to an O.D. 600 of 0.9. This was
induced with 1mM IPTG overnight at 30°C. Periplasmic protein was extracted using a
protocol adapted from Springer Lab Manual (2001). The overnight culture was
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centrifuged at 5000g for 30min at 4°C. The pellet was resuspended in 35ml of cold
spheroblast solution (50mM Tris-HCL pH 8.0, 20% w/v sucrose and 1mM EDTA pH
8.0). This was incubated on ice for 20min with occasional shaking. The solution was
spun at 6200g for 15min at 4°C. The supernatant was collected and spun at 30,000g for
30min at 4°C to remove any remaining debris. The supernatant containing the
periplasmic extract was saved.

3.13 Dot Blot
A nitrocellulose membrane was blotted with 2µl of CD20 antigen at different
concentrations (200µg/ml, 10µg/ml, 5µg/ml, 2.5µg/ml, and 1.25µg/ml) and allowed to
dry. The membrane was blocked with 5% BSA in PBS for 30min. The membrane was
incubated with the periplasmic extract for 30min, then washed with TBST. A 1:1000
dilution of Protein L-HRP conjugate (Pierce, Rockford, IL) was incubated with the blot
for 30min. The membrane was washed and incubated with ECL reagents (Amersham,
Piscataway, NJ), and developed. A second dot blot was performed using the biotinylated
fusion protein obtained as antigen, and Clone 3 as the primary antibody.
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CHAPTER 4
RESULTS
4.1 Fusion Protein Data
RNA obtained from Raji cells was reverse transcribed into cDNA. The sequence
of CD20 was obtained from NCBI (Accession number: NM-021950) and the open
reading frame (ORF) found using ORF Finder (NCBI). Primers were designed to amplify
the 894bp ORF. Figure 4.1 shows the expected CD20 ORF band.

.

Figure 4.1 CD20 ORF obtained after RT-PCR of Raji cell RNA using CD20 ORF
primers.
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The cDNA obtained was ligated into PCR 2.1 (Invitrogen). Competent Top 10 E
coli cells were transformed with the ligation reaction. DNA obtained from resulting
clones was restricted with KpnI to determine which clone had the insert in the correct
orientation. A 302bp band was expected if the orientation was correct, and a 688bp band
if wrong. Figure 4.2 shows Clone 10 (PCR2.1-CD20) with the correct orientation.

Figure 4.2 Kpn I restriction digest of PCR2.1-CD20 clones
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The extracellular fragment of CD20 (CD20-EC) was predicted to be between
nucleotides 426 to 555 (NCBI NM_021950). Primers designed to amplify a larger
fragment (nucleotides 418 to 571) were used in PCR. A 150bp band was expected after
electrophoresis of PCR products. The primers were also designed to add an NruI site at
the 5’ end, a stop codon and an extra base at the 3’ end, to maintain the reading frame of
the original sequence.

Figure 4.3 Amplification of the CD20 extracellular fragment (CD20-EC) from PCR2.1CD20.

33
.

The CD20-EC fragment obtained was ligated into PCR2.1 and restricted with Sac
I to find the correct clone. A 95bp was expected if the insert was in the correct orientation.
In Figure 4.4, Samples 8 and 12 appeared to have the right size bands and thus were
sequenced.

Figure 4.4 SacI restriction digest of PCR2.1-CD20-EC

PCR2.1-CD20-EC Samples 8 and 12 were sequenced using CD20-EC forward
and reverse primers. The results obtained from sequencing PCR2.1-CD20-EC were
aligned with the expected sequence of the CD20 extracellular fragment, NruI restriction
site and the TAA stop codon (Table 1). PCR2-1-CD20-EC #12 had the insert in the
correct orientation.

TCGCGAAAATATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTA
TTAGAGCTCACACACCATATATTAACATATACAACTGTGAACCAGCTAATCCC
TCTGAGAAAAACTCCCCATCTACCCAATACTGTTACAGCATACAATCTCTGTT
CTAA

Table 1: Expected DNA sequence of CD20-EC fragment with preceding NruI site, and
stop codon.
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Figure 4.5 Alignment of the obtained PCR2.1-CD20-EC sequence with the known
CD20-EC insert sequence.
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The CD20-EC portion was cut out of PCR2.1-CD20-EC #12 using restriction
enzymes NruI and NotI. Pinpoint Xa Vector (Invitrogen), a protein expression vector,
was restricted with the same enzymes to create an insertion point in its multiple cloning
site for the insert. The two fragments were ligated to form PXCD20-EC. Rosetta E coli
cells (Invitrogen) were transformed with the ligation reaction. Miniprep DNA isolated
from different clones was restricted with NruI and NotI to confirm the presence of the
insert.

Figure 4.6 NruI and NotI Digest of PXCD20-EC to verify the presence of the CD20-EC
insert.
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Miniprep DNA from a sample was sequenced using SP6 Promoter and Pinpoint
Vector sequencing primers (Invitrogen). The expected insert was present in the correct
orientation.

Figure 4.7 Alignment of PXCD20-EC sequence with the expected insert sequence
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Rosetta E. coli cells transformed with the constructed vector, and expressing the
biotinylated fusion protein were cultured. Bacterial pellets were saved before and after
induction of protein expression using IPTG. A western blot comparing protein expression
before and after induction using a Streptavidin-HRP conjugate was performed. A 20kDa
fusion protein band was expected. The expected fusion protein band was more prominent
after induction.

Figure 4.8 Western Blot Analysis of Protein Expression before and after induction.
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Protein in inclusion body form was extracted from the bacterial pellets obtained
after induction. The proteins were folded in vitro to form their native active state
(Rudolph & Lilie, 1996). A protein gel showed the expected 20kDa fusion protein band.

.

Figure 4.9 SDS PAGE of refolded fusion protein.

Western blot analysis of the re-folded protein using HRP-conjugated Streptavidin
was performed. The expected 20kDa band is shown.

Figure 4.10 Western blot of refolded fusion protein.
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4.2 ScFv Isolation Data
Western blot under denaturing conditions of protein extracted from 293T/CD20,
293T/17, and Raji cells using a 1: 250 dilution of mouse anti-CD20 monoclonal antibody
and a 1:2000 dilution of goat anti-mouse HRP-conjugated antibody was performed.
293T/17 which does not express CD20 showed no bands, while the transfected cell line,
293T/CD20, and Raji cells which express CD20 normally showed the expected 33kDa
CD20 band.

Figure 4.11 Western blot of protein extracted from the 293T/CD20, 293T17 and Raji cell
lines using anti-CD20 monoclonal antibody.
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Protein extracted from the CD20 transfected-T-REx CHO cell line (CD20/TREXCHO), after 24hrs of induction was compared with protein extracted from the same
number of cells from the remaining cell lines. As expected, Raji, 293T/CD20 and
CD20/T-REXCHO expressed CD20 while the parental cell lines 293T/17 and TREXCHO did not. The lower lever of CD20 expression on CD20/T-REXCHO could be
due to low plasmid copy number.

Figure 4.12 Western blot comparing protein extracted from all cell lines using anti-CD20
antibody.
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Phage eluted after selection was titered before and after amplification.

Averaged Titer Data
Eluate Titer (pfu/ml) Amplified Phage Titer (pfu/ml)
R1 3.10 x 1005
3.7 x 1012
R2 2.80 x 1006
4.75 x 1011
R3 2.49 x 1004
4.00 x 1011

Table 2: Titers of selection obtained phage before and after amplification

Phage Titer

Phage Titer [log(pfu/ml)]

Eluted Phage

Amplified Phage

14
12
10
8
6
4
2
0
R1

R2

Round of Selection

Figure 4.13 Titer of eluted and amplified phage
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R3

Polyclonal ELISA in duplicate using 10µg/ml of CD20 antigen to detect the
binding of 10µl of eluted phage from each round of selection. The secondary antibody
used was HRP-anti-M13 (Pharmacia). TMB reagents (Pierce, Rockford, IL) were used to
detect the reaction. Helper phage (KM13) and blocking buffer (BSA in PBS) were used
as controls.

Polyclonal ELISA
1.2

O.D. [450-655]

1
0.8
0.6
0.4
0.2
0
R1

R2

R3

CONTROLS

Round of Selection

Figure 4.14 Polyclonal ELISA in duplicate of eluted phage from the first three rounds of
selection.
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PCR analysis to amplify the 934bp scFv insert, was performed on four random
clones from each round of screening. The positive control C is an anti-ubiquitin scFv
clone provided with the library (Geneservice, Cambridge, UK). Clones from Rounds 1 to
3 of selection showed the expected band, while none of the Round 4 clones displayed any
inserts.

Figure 4.15 PCR analyses of clones from four rounds of selection to determine the
presence of the scFv insert.
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More clones from Rounds 2 and 3 of selection were chosen for further PCR
analysis. Most clones screened displayed the expected scFv band. The anti-ubiquitin scFv
clone was used as a positive control. Clone #3 from Figure 4.17 was chosen for further
analysis.

Figure 4.16 PCR analyses of ten clones from Round 2 of selection.

Figure 4.17 PCR analyses of ten clones from Round 3 of selection.
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ScFv inserts from 4 random clones from the third round of selection, were cut out
of the phagemid vector using NotI and NcoI restriction enzymes. HaeIII digest of the
inserts showed an identical pattern.

Figure 4.18 HaeIII digest of scFv inserts.
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Phage obtained from the third round of selection was titered to obtain individual
colonies. The colonies were cultured and co-infected with helper phage, to enable
propagation of phage particles. Monoclonal ELISA was done on these cultures to
determine their CD20 binding using 5µg/ml CD20 antigen, and HRP-conjugated AntiM13 (Pharmacia) as the secondary antibody.

Monoclonal ELISA
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Figure 4.19 Monoclonal ELISA on clones from Round 3 of selection.
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Based on ELISA and PCR results, Clone #3 was selected for further study. Clone
#3 phage was used to infect HB2151, a non-suppressor E. coli strain, allowing the scFv
protein produced to be targeted to the periplasmic space of the bacteria. A dot blot was
performed on the periplasmic protein extracted from Clone #3 using varying
concentrations of CD20 antigen to determine its binding to CD20. HRP-conjugated
protein L was used as the secondary antibody, and binding was visualized using ECL
reagents. Binding was evident for the first three dilutions shown.

Figure 4.20 Dot blot showing the binding of Clone #3 scFv to CD20 antigen.
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The biotinylated fusion protein created in the first study was blotted onto a
nitrocellulose membrane to determine if Clone #3 bound to it. CD20 antigen (180µg/ml)
was blotted as a positive control, as Figure 4.20 shows that Clone #3 does bind to it.
Figure 4.21 shows that Clone #3 periplasmic protein does bind to the created fusion
protein.

Figure 4.21 Dot blot of the biotinylated fusion protein and Clone #3 scFv-containing
periplasmic protein.
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CHAPTER 5
DISCUSSION
The first objective of this project was to create a CD20 fusion protein for phage
antibody selection and characterization. By fusing the extracellular fragment of CD20
with the bacterial in vivo biotinylation tag, the recombinant fusion protein produced in E.
coli could be conveniently coated onto magnetic streptavidin beads or streptavidin coated
microplates for phage selection or phage ELISA. Sequencing analysis of the plasmid
construct confirmed correct fusion between the two open reading frames. Western blot
analysis of induced bacterial pellets, and the protein obtained after the refolding protocol
adapted from Rudolph and Lilie (1996), using Streptavidin-HRP conjugate, confirmed
the creation of a functional biotinylated fusion protein. To purify the refolded
recombinant fusion protein, the SoftLink™ Soft Release Avidin Resin (Promega,
Madison, WI) was used for batch processing.
The next objective was to screen for anti-CD20 scFvs from a naïve human library.
The scFvs generated would be true human sequences, drastically decreasing
immunogenicity associated with murine and chimeric antibodies when used in vivo.
ScFvs, like their parent antibodies and other antibody fragments, can be exploited in
various ways in diagnosis and therapy of cancer and non-cancerous conditions. High
affinity scFvs can be coupled to high affinity Fc variants to obtain a highly specific and
potent monoclonal antibody against a target of choice. Target-specific antibody
fragments can be labeled and employed in tumor imaging in vivo (Hamdy et al., 2005).
ScFvs can be conjugated to molecules which they then deliver to the target cells. These

50
.

molecules could be therapeutic drugs which allow proper functioning of the target cell, or
toxins which kill the neoplastic target cell.
In the present study, a cell based procedure was used for phage selection. Under
this condition, the interaction of phage particles with CD20 antigen would occur at the
cell membrane microenvironment, which mimics in vivo conditions much better than
other methods. Though there are tumor cell lines known to over-express CD20 proteins
such as Raji, two CD20 cDNA transfected cell lines, 293T/CD20 and CD20/T-Rex CHO,
were used in the present study to have a better negative control for depletion selections.
The first round of selection was performed on 293T/CD20 cells, and the remaining three
rounds were performed on CD20 transfected T-Rex™ CHO cells. The 293T/CD20 cell
line was created through the transduction of a lentivector plasmid FUW, into which
human CD20 cDNA had been cloned. The vector was pseudotyped with vesicular
stomatitis virus (VSVG) before transduction of 293T cells (Yang et al., 2006). Stable
expression of CD20 was confirmed by Western blot analysis of proteins extracted from
the cell lines before each round of selection.
The second cell line used for selection was a tetracycline-regulated expression
CHO cell line, stably transfected with an expression vector into which the CD20 ORF
had been cloned. Selection was done 24hrs after induction. The expression of CD20 was
low compared to that of 293T/CD20 as observed by Western blot analysis. Alternating
the two different cell lines for selections would not only increase the depletion of phage
which bound non-specifically to different antigens on the surface of the previous cell line
(Heitner et al., 2006), but this would also increase selection stringency when the second
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cell line used has less target antigen expression, as is the case in the current study. The
sharp decrease in phage titer after selection on the second cell line, as well as the
decrease in polyclonal ELISA signal, suggests that use of the second cell line did deplete
some of the non-specific binding phages. As mentioned previously, the CD20/T-Rex
CHO cell line had a lower CD20 antigenic density in comparison to 293T/CD20. Using
the lower density cell line, also allows the depletion of low affinity antibodies in favor of
high affinity ones. The decreasing selection time and increasing stringency of washes
allowed for the selection of phage which bound quickly and tightly to the CD20 target.
PCR analysis of the phage should yield a 935bp band if there is an scFv insert
present (Geneservice, Cambridge, UK). PCR analysis of the eluted phage showed that a
very high percentage of phages from the first to the third rounds of selection showed the
antibody fragment inserts, while this fragment appeared to have been lost in a lot of
phages from the fourth round of selection. This suggests that while increased rounds of
selection may increase the specificity of the phages obtained, it also increases the chance
of the insert-carrying phage being lost. Stop codons and frame shifts originated during
construction of the library lead to clones which do not express the scFv-pIII fusion
protein. Bacteria carrying these insert-less phage have increased growth rates and
produce more phage, thereby decreasing the population of phage expressing scFv-pIII
with sequential growth passages (Kramer et al., 2003). In addition, insert-free phages are
also likely to over-take phage cultures with consecutive rounds of amplification and
selection (Trepel et al., 2001). Thus clones were chosen from the second and third rounds
of selection for analysis. Most colonies from rounds two and three contained the expected

52
.

935bp band as well as an approximately 2kb band which could be due to multiple inserts
in some cases, and more likely due to non-specific amplification.
Comparing monoclonal ELISA data with PCR data, two clones: #3 and #21, were
chosen for the production of soluble antibody fragments. Periplasmic protein was
extracted from cultures and its affinity for CD20 antigen tested via a dot blot, using HRPconjugated Protein L as the secondary antibody, which binds to the variable domain of
the kappa light chain (Nilson et al., 1992). Clone 3 showed significant binding at
decreasing concentrations of CD20 antigen, while Clone 21 did not show significant
binding.
The next steps would be further screening of clones from the second and third
rounds to select insert-bearing phages and test their affinity for CD20. While PCR
screening, monoclonal ELISA and dot blot data prove Clone 3 binds to CD20 antigen,
DNA sequencing analysis would further confirm the presence of both a heavy chain and a
kappa light chain. For better expression, the insert can be transferred to a protein
expression vector, such as pET22b, to expedite production and purification of the
antibody fragment. Flow cytometry or Surface Plasmon Resonance (SPR) could be used
to elucidate the binding affinity and binding kinetics of the scFv. Cytotoxicity and
apoptosis assays can be performed to determine the effect of the scFv on CD20
expressing cells both in vitro and in vivo.
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CHAPTER 6
CONCLUSIONS
Humax-CD20, the fully human anti-CD20 monoclonal antibody currently in
clinical trials, shows the advantages human antibodies possess over murine and chimeric
ones in the treatment of lymphoma, arthritis, SLE and other ailments (Genmab, 2007).
The smaller size of scFvs allows them to be great candidates for imaging tumors when
conjugated to radionuclides. The risk of immunogenicity is minimal, reducing side
effects when administered to patients. The addition of genes encoding scFvs to viral and
non-viral vectors enhances specificity without any added toxicity. ScFvs are also capable
of neutralizing viruses and toxins (Blazek & Celer, 2003).
The aim of this study was to isolate a human scFv specific for CD20 antigen. Cell
lines provided the antigen in a state more comparable to its native state. The use of two
different cell lines as the sources of antigen decreased the chances of isolating clones
which bound non-specifically to other surface antigens (Heitner et al., 2006). Clones
selected from the second and third rounds of selection maintained their inserts and
showed some specific binding to CD20 antigen, while clones from the fourth round of
screening did not appear to have any inserts. This agrees with previous findings which
suggest that there is a limit on the number of selection cycles a phage library can be put
through before insert-free phages overtake set-up cultures (Trepel et al., 2001).
A clone was isolated (Clone 3) which bound to CD20 as observed by ELISA and
dot blot analysis. Future work would characterize this clone and screen more clones from
the second and third rounds of selection.
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